Results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102) conducted on a previously reported Phase II study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with the trial drug in combination with chemotherapy improved median overall survival (OS) in patients whose tumors exhibited high MET protein expression. Full results of the study will be presented in an oral presentation at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 (Abstract 4005, 4:45 p.m. – 5:00 p.m. CDT, E Hall D1).
Gastric, or stomach, cancer is the second most common cause of cancer-related death in the world, accounting for 736,000 deaths worldwide in 2008. The highest mortality rates are in Eastern Asia. An estimated 21,320 new cases of gastric cancer will be diagnosed in the United States in 2012, and about 10,540 Americans will die from this type of cancer. Gastric cancer is a disease that mostly affects older people with nearly two-thirds of patients age 65 and older.
Rilotumumab is an investigational fully human monoclonal antibody designed to inhibit the hepatocyte growth factor/scatter factor (HGF/SF): MET pathway. Rilotumumab has an additive effect when combined with chemotherapeutic agents.
The phase II, three-arm trial, 121 patients were randomized 1:1:1 to receive epirubicin, cisplatin and capecitabine (50mg/m(2) IV day 1, 60mg/m(2) IV day 1, 625mg/m(2) BID orally days 1-21, respectively) in combination with two different dose levels of rilotumumab (Arm A 15 mg/kg Q3W, n=40; Arm B 7.5 mg/kg Q3W, n=42) or placebo (Arm C, n=39). The primary endpoint of the study was PFS. Secondary endpoints included OS, objective response rate (ORR) and safety. In the biomarker analysis, 90 patients were evaluated for MET protein levels using an immunohistochemistry test. Twenty-seven patients from the rilotumumab treatment arms and 11 patients who received placebo were found to have tumors with high MET expression, defined as greater than 50% of tumor cells testing positive for the MET protein.
In the exploratory analysis, the addition of rilotumumab to chemotherapy in patients with gastric tumors with high MET expression improved median OS from 5.7 months to 11.1 months (HR = 0.29, 95% CI, 0.11 – 0.76). Conversely, in patients with gastric tumors with low MET expression, the addition of rilotumumab to chemotherapy was associated with a trend towards unfavorable OS (HR = 1.84, 95% CI, 0.78 – 4.34). These results have led Amgen to plan a Phase III study to confirm the efficacy of rilotumumab in advanced gastric and gastroesophageal cancer with high MET expression.
“These data are the first to demonstrate a potential biomarker for treatment with rilotumumab in gastric cancer, the second leading cause of cancer deaths worldwide,” said Michael Severino, M.D., senior vice president, global development and corporate chief medical officer at Amgen. “Personalized medicine has the potential to transform cancer care, and by leveraging our understanding of biology and the mechanism of disease, we hope to identify safe and effective new treatments for patients who aren’t well-served by current therapies.”
Primary results of the study were presented at the 2011 European Multidisciplinary Cancer Congress and showed that the primary endpoint of progression-free survival (PFS) had a trend towards a better outcome with rilotumumab plus chemotherapy. The addition of rilotumumab to chemotherapy improved median PFS from 4.2 months to 5.6 months (HR = 0.64, 80% CI, 0.48 ? 0.85). The secondary endpoint of OS also trended in favor of rilotumumab, with improved median OS from 8.9 months to 11.1 months (HR = 0.73, 80% CI, 0.53 ? 1.01).
The most common adverse events seen in the rilotumumab plus chemotherapy arms included peripheral edema, neutropenia, anemia, thrombocytopenia and deep vein thrombosis. There were no major differences in adverse events between the two rilotumumab arms.
For more information:
Giordano S. Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer
Curr Opin Mol Ther. 2009 Aug;11(4):448-55.
 Cancer.World Health Organization(WHO) website. Last accessed April 26, 2012.
Stomach Cancer. American Cancer Society (ACS) website. Last accessed April 26, 2012.
 Stomach Cancer. American Cancer Society website. Last accessed April 26, 2012.
Copyright ? 2012 InPress Media Group/Sunvalley Communication. All rights reserved.
Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.